Description

DIAMICRON XR 60 MG (1X15)

Indications

DIAMICRON XR 60 MG is an oral medication indicated for the management of type 2 diabetes mellitus. It is typically used in conjunction with diet and exercise to improve glycemic control in adults. The active ingredient in DIAMICRON XR is gliclazide, which belongs to the class of drugs known as sulfonylureas. This medication is particularly beneficial for patients who are unable to achieve adequate glycemic control with diet and exercise alone.

Mechanism of Action

The primary mechanism of action of gliclazide, the active component of DIAMICRON XR, involves stimulating the pancreas to release insulin. It achieves this by binding to specific receptors on pancreatic beta cells, which enhances insulin secretion in response to elevated blood glucose levels. Additionally, gliclazide has been shown to improve insulin sensitivity in peripheral tissues, thereby facilitating better glucose uptake by cells. This dual action contributes to a reduction in blood glucose levels and assists in maintaining overall glycemic control.

Pharmacological Properties

DIAMICRON XR is characterized by its extended-release formulation, which allows for once-daily dosing. This formulation ensures a steady release of gliclazide over a 24-hour period, providing consistent glycemic control with minimal peaks and troughs in blood glucose levels. The pharmacokinetics of gliclazide indicate that it is well absorbed from the gastrointestinal tract, with peak plasma concentrations occurring approximately 6 to 12 hours after administration. The drug is primarily metabolized in the liver and excreted through the urine, with a half-life of about 10 to 12 hours.

Contraindications

DIAMICRON XR is contraindicated in individuals with a known hypersensitivity to gliclazide or any of the excipients in the formulation. It should not be used in patients with type 1 diabetes mellitus or diabetic ketoacidosis, as these conditions require different therapeutic approaches. Additionally, the use of DIAMICRON XR is contraindicated in patients with severe renal or hepatic impairment, as these conditions can significantly affect the metabolism and elimination of the drug.

Side Effects

Like all medications, DIAMICRON XR may cause side effects. Common adverse effects include hypoglycemia (low blood sugar), which can manifest as dizziness, sweating, tremors, and palpitations. Other potential side effects include gastrointestinal disturbances such as nausea, vomiting, and diarrhea. Rare but serious side effects may include allergic reactions, liver dysfunction, and blood dyscrasias. Patients are advised to monitor for any unusual symptoms and report them to their healthcare provider promptly.

Dosage and Administration

The recommended starting dose of DIAMICRON XR is typically 30 mg once daily, which may be adjusted based on individual patient response and glycemic control. The maximum recommended dose is 120 mg per day. It is essential to take the medication with food, preferably during breakfast, to minimize the risk of hypoglycemia. Patients should be regularly monitored for blood glucose levels, and dosage adjustments may be necessary based on these readings and any changes in the patient’s condition.

Interactions

DIAMICRON XR may interact with several other medications, which can either potentiate or diminish its hypoglycemic effects. Drugs that may enhance the effects of gliclazide include other antidiabetic agents, certain antibiotics, and antifungal medications. Conversely, medications such as corticosteroids, diuretics, and certain antihypertensives may reduce the effectiveness of DIAMICRON XR. It is crucial for patients to inform their healthcare provider of all medications and supplements they are taking to avoid potential interactions.

Precautions

Patients using DIAMICRON XR should exercise caution, particularly those with a history of hypoglycemia, as they may be more susceptible to its effects. Regular monitoring of blood glucose levels is essential to prevent episodes of hypoglycemia. Additionally, patients with renal or hepatic impairment should be closely monitored, and dosage adjustments may be necessary. It is also important to educate patients about recognizing the signs and symptoms of hypoglycemia and how to manage it effectively.

Clinical Studies

Clinical studies have demonstrated the efficacy and safety of DIAMICRON XR in managing type 2 diabetes. In randomized controlled trials, patients treated with gliclazide showed significant reductions in HbA1c levels compared to those receiving placebo or other antidiabetic agents. The extended-release formulation has been associated with improved adherence due to its once-daily dosing regimen. Furthermore, studies have indicated that gliclazide may have beneficial effects on cardiovascular outcomes, making it a suitable choice for patients with comorbid conditions.

Conclusion

DIAMICRON XR 60 MG is an effective and well-tolerated option for the management of type 2 diabetes mellitus. Its unique extended-release formulation allows for convenient once-daily dosing while providing consistent glycemic control. As with any medication, it is essential for patients to work closely with their healthcare providers to ensure optimal treatment outcomes and to address any concerns regarding side effects or interactions with other medications. With proper management and monitoring, DIAMICRON XR can play a vital role in achieving and maintaining target blood glucose levels in individuals with type 2 diabetes.